Immunotech Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AIM ImmunoTech (NYSE:AIM – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares […]

AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report)’s stock price traded down 9.1% on Tuesday . The company traded as low as $0.35 and last traded at $0.35. 344,384 shares changed hands during trading, an increase of 68% from the average session volume of 205,318 shares. The stock had previously closed at $0.39. AIM ImmunoTech […]

The Biden campaign and other Democrats believe they have several options to get the 270 Electoral College votes needed to win another four years in office. But retaining Michigan, Pennsylvania and... -May 16, 2024 at 06:20 am EDT - MarketScreener

AIM ImmunoTech Inc. (NYSE: AIM) shares poked ahead to begin the first full week of May, having announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed ...

OCALA, Fla., May 06, 2024 -- AIM ImmunoTech Inc.   today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® , AIM’s dsRNA product candidate being...